Psoriasis is considered to be a persistent skin disorder that is characterized mainly by skin irritation and scaly rashes where the skin cells multiply up to 10 times faster than normal. Psoriasis majorly affects the knees, elbows, and scalp. The major objective of the therapy for this disease is to stop the skin cells from growing so quickly. The therapeutic approach for psoriasis depends upon the severity and amount of skin affected by the same.
Treatment methods for psoriasis include topical treatments, injecting steroids, and internal medication along with radiation therapy in severe cases. The major factors that fuel the growth of the market are increase in the incidence of psoriasis along with skin disorders associated with it globally. In addition, rising awareness among people regarding different treatments available in the market supplements the growing demand for psoriasis therapies.
However, health risks posed due to the medication along with high costs of therapies restrain the growth of the psoriasis therapeutics market. Albeit, increasing development of new biologics and novel pipeline drugs will offer profitable opportunities for psoriasis therapeutics.
The report segments the market on the basis of drug class, molecule type, route of administration, and region. Based on drug class, the market is divided into TNF inhibitors, PDE4 inhibitors, interleukin blockers, and others. Based on molecule type, the market is classified into biologics and small molecules. Based on route of administration the market is divided into oral, parenteral, and topical. Based on region, it has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players profiled in this market are Astellas Pharma Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, F. Hofffmann-La Roche, GlaxoSmithKline plc, Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., Biocon Limited, Eli Lilly and Company, and G & W Laboratories Inc.
- The study provides an in-depth analysis of the global psoriasis therapeutics market, with current trends and future estimations to elucidate imminent investment pockets.
- It presents a quantitative analysis from 2016 to 2023 to enable stakeholders to capitalize on prevailing market opportunities.
- Extensive analysis of the market by type assists in understanding various forms of psoriasis therapeutics available.
- Key players have been profiled and their strategies thoroughly analyzed, which predict the competitive outlook of the market.
Psoriasis Therapeutics Market Key Segmentation:
By Drug Class
- TNF Inhibitors
- PDE4 Inhibitors
- Interleukin Blockers
By Molecule Type
By Route of Administration
- North America
- Rest of Europe
- Rest of Asia-Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA